Ovid Therapeutics
OVID · NASDAQ
$2.36+$0.19 (+8.76%)TodayMarket closed ·
Prev close $2.17
Who owns OVID
Largest institutional holders, from their latest 13F filings
The 10 largest institutions hold 56.0% of OVID’s shares.
- Janus Henderson Investors11.1%
- Eventide Asset Management, LLC6.3%
- RA Capital Management, LP5.6%
- Affinity Asset Advisors LLC5.4%
- Next 6 largest institutions27.5%
- All other shareholders44.0%
| Holder | Shares | % of shares |
|---|---|---|
| Janus Henderson Investors | 20.74M | 11.11% |
| Eventide Asset Management, LLC | 11.81M | 6.33% |
| RA Capital Management, LP | 10.50M | 5.63% |
| Affinity Asset Advisors LLC | 10.14M | 5.44% |
| BlackRock Institutional Trust Company, N.A. | 10.01M | 5.36% |
| Sirenia Capital Management LP | 9.48M | 5.08% |
| Takeda Pharmaceutical Company Limited | 8.78M | 4.71% |
| State Street Investment Management (US) | 7.90M | 4.23% |
| Vanguard Capital Management, LLC | 7.76M | 4.16% |
| Adar1 Capital Management LLC | 7.42M | 3.97% |
Largest mutual fund holders
| Holder | Shares | % of shares |
|---|---|---|
| Eventide Healthcare & Life Sciences Fund | 9.92M | 5.31% |
| Vanguard Total Stock Market Index Fund | 5.65M | 3.03% |
| State Street SPDR S&P Biotech ETF | 5.19M | 2.78% |
| iShares Russell 2000 ETF | 3.87M | 2.07% |
| Federated Hermes Kaufmann Small Cap Fund | 2.38M | 1.28% |
Insider trades
Form 4 filings by officers, directors and large holders
Insiders made no open-market buys or sales of OVID in the last 6 months.
| Insider | Type | Shares | Value |
|---|---|---|---|
| Carter Charles Ross | Award | 50.00K | — |
| Greka Anna | Award | 130.00K | — |
Short interest
Settled Sep 30, 2026
- Shares short
- 18.95M
- Days to cover
- 8.93
- % of shares outstanding
- 10.15%
- Average daily volume
- 2.12M
- Change since last report
- −10.4%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.